Nuclear factor of activated T cells 1 (NFATc1) is a transcription factor activated by T cell receptor (TCR) and Ca 
Abstract
Nuclear factor of activated T cells 1 (NFATc1) is a transcription factor activated by T cell receptor (TCR) and Ca NAFTc1 and NFATc2 are the main isoforms expressed in T-cells critical in regulating early gene transcription in response to T-cell receptor (TCR)-mediated signals [1] [2] [3] . In resting T-cells, NFAT transcription factors are located in the cytosol in an inactive, phosphorylated state. Upon TCR stimulation, NFAT is activated by calcium flux released from the endoplasmic reticulum and the extracellular environment through store-operated channels. Induced intracytoplasmic calcium promotes calmodulin, a calcium sensor protein which activates the phosphatase calcineurin.
Calcineurin dephosphorylates NFAT resulting in its translocation into the nucleus where it cooperates with other transcription factors promoting cell specific gene transcription [3, 4] .
The expression of NFATc1 in T-cells is initiated by two distinct promoters, resulting along with alternative splice/polyadenylation events in six isoforms: NFATc1αA-C and NFATc1βA-C [5, 6] .
NFATc1αA has been shown to be strongly induced following TCR stimulation and is maintained by a positive autoregulation which enables a massive synthesis and facilitates T-cells to exert effector functions and escape from apoptosis [5, [7] [8] [9] . Cytotoxic effector functions are mediated by CD8 + T-cells via the secretion of inflammatory cytokines [10, 11] . A recent study described that NFATc1-deficient cytotoxic T-cells showed reduced cytotoxicity against tumour cells.
Furthermore, transcriptome analysis demonstrates diminished RNA levels of numerous genes in NFATc1 −/− CD8 + T-cells, including Il2 [9] . Interleukin-2 (IL-2) is one of the first molecules that has been shown to be induced by NFATc1 [12] and is important for T-cell activation, proliferation and survival [13, 14] . Furthermore, IL-2 influences the generation of memory CD8 + T-cells classified into central memory (TCM), effector memory (TEM) and tissue-resident memory (TRM) CD8 + T-cells that differ in their tissue homing capacity and effector functions [13, [15] [16] [17] . In most of the established tumours, tumour-infiltrating lymphocytes (TILs) are found to be exhausted leading to cancer immune evasion. One remarkable feature of functionally exhausted T-cells is the expression of inhibitory checkpoint receptors which desensitize TCR
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Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/0008-5472. signaling leading to functional impairment of T-cell activation. Based on these findings, cancer immunotherapies have been developed that reactivate exhausted TILs by blocking inhibitory checkpoint receptors [18] [19] [20] . Programmed cell death (PD)-1 is one of the most successful checkpoint target in different cancer types including non-small cell lung cancer (NSCLC).
Nevertheless, only ~30% of patients are responsive to this therapy, and there is a need to find alternate regulators to improve present approaches [19] [20] [21] [22] [23] . NFATc1 has been shown to induce the expression of PD-1 upon T-cell activation [24] . But there is still a contradiction regarding the influence of αPD-1 antibody treatment on NFATc1 in T-cells. Triggering of PD-1 by its ligand PD-L1 expressed on tumour cells induces the inhibition of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway. Akt normally negatively regulates the glycogen-synthase kinase 3 (GSK3) which inhibits NFATc1 [3, 25, 26] . Blocking PD-1 by αPD-1 antibodies restores TCR signaling and ensured the activation of Akt which inhibits GSK3 and promotes the activation of NFATc1 which induces T-cell activation and effector functions [7, 9, 25] . Thus, NFATc1 could be a key regulator in αPD-1 anti-cancer immunotherapy. Research. 
Materials and Methods

Human subjects and study population
This study was performed at the Friedrich-Alexander-University of Erlangen in Germany and was approved by the ethics review board of the University of Erlangen (Re-No: 56_12B; DRKS-ID: DRKS00005376). Fifty-eight patients that suffered from NSCLC underwent surgery and gave their approval to be enrolled in this study in an informed written consent. The patient studies were conducted in accordance with the ethical guidelines of the Declaration of Helsinki. tissue), the peri-tumoural area (PT: up to 2 cm away from the solid tumour) and from the tumour free control area (CTR: >5cm away from the solid tumour). This cohort of NSCLC patients was previously described [27] .
Protein Extraction and Western blot analyzes
For protein extraction, lung tissue samples were lysed in RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA) with added inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), followed by homogenization using the SpeedMill PLUS (Analytik Jena, Jena, Germany) and innuSPEED lysis Tube P (Analytik Jena). After centrifugation (5 min, 3000 r.p.m., 4°C), supernatants were incubated on ice for 45 min, followed by centrifugation (1x 5 min, 3000 r.p.m., 4°C; 1x 45 min, full speed, 4°C).Finally,protein concentration was calculated after using Bradford Assay (Protein Assay Dye Reagent Concentration, Bio-Rad, Munich, Germany). Western blot analysis to detect NFATc1 (1:250; sc-1149, Santa Cruz, Heidelberg, Germany), pNFATc1 (1:250; sc-32978, Santa Cruz) and β-Actin (1:500, sc-1616, Santa Cruz) was performed as previously described [28] 
Double immunohistochemistry (IHC) of NFATc1 and CD3 on paraffin-embedded lung tissue sections
Immunohistochemistry was performed on paraffin-embedded sections. Before staining, paraffin was removed from the slides by incubation at 72°C for 30 min and treatment with Roti-Histol (Carl Roth, Karlsruhe, Germany) two times for 10 min. The tissue sections were then rehydrated by immersion in ethanol-series with descending concentrations (100%, 95%, 70%) for 3 min each and in deionised water for 1 min, followed by blocking endogeneous peroxidase in 3% H 2 O 2 (in methanol) for 20 min. Heat-induced antigen retrieval was performed as previously described [27] using 1 mM Tris-EDTA wash buffer. Afterwards, slides were incubated with primary antibody to CD3 (1:100, RBK024, Zytomed Systems GmbH, Berlin, Germany) overnight at 4°C. After different washing steps and detection of the primary antibody following the manufacture instructions of the ZytoChem-Plus AP Polymer Kit (POLAP006, Zytomed Systems GmbH) the second antibody to NFATc1 (1:50, sc-7294, Santa Cruz) was applied for 2h at RT. The second antibody was detected following the manufacture instructions of the Dako EnVision Detection System Kit (K4065, Hamburg, Germany). Slides were covered with coverslips using Aquatex (108562, Merck, Darmstadt, Germany). Negative controls were not treated with the primary antibodies, the other steps remain the same. Stained slides were scanned using the digital slide scanner (Scan 150, 3D Histech Ltd, Budapest, Hungary) and NFATc1 + CD3 + cells were quantified using the Definiens Tissue Studio 4.1 software (Definiens, Munich, Germany) at the
Total cell isolation and flow cytometry analyzes of human cells
Frozen human tissue samples were cut into small pieces using scalpels (1-3 mm 2 ) followed by the preparation of single-cell suspensions using the Tumor Dissociation Kit, human (Miltenyi Biotec, Bergisch Gladbach, Germany) and the gentleMACS™ Dissociator (Miltenyi Biotec) according to the manufacturer's instructions. The resulting single-cell suspension was washed and ammonium-chloride-potassium (ACK) lysis buffer was applied as previously described [27] . For 
Cell lines
The human A549 cell line was purchased authenticated from the ATCC bank (Manassas, Virginia, USA 
RNA Isolation and cDNA synthesis
Human lung tissue samples were homogenized using Precellys Lysing Kits (Bertin Technologies, Montigny-le-Bretonneux, France) using the benchtop homogenizer Minilys (Bertin Technologies) as described in the manufacturer's protocol. Total RNA was isolated using peqGold RNA Pure (Peqlab, Erlangen, Germany) according to manufacturer´s instructions. RNA was reversetranscribed into cDNA using the RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, St.
Leon-Rot, Germany) in accordance to the manufacturer's instructions. 
Luminescence Assay
For luminescence analysis 7 x 10 3 LL/2-luc-M38 (LL/2) cells were cultured in a 96-well plate and incubated for 24h at 37°C, 5% CO 2 in DMEM medium supplemented with 10% FCS, 1% Pen/Strep and 1% L-Glu. After 24h, supernatants (SN) were removed, cells were washed in PBS and incubated with either 20% lymph node-conditioned medium (LNCM) or lung-conditioned medium (LUCM). For preparation of LNCM or LUCM, total cell lysates of dLNs or lungs were cultured for 24h in the presence of αCD3 (10 μg/ml; BD Bioscience) and αCD28 (1 μg/ml; Biolegend) antibodies or in the presence of αPD-1 mAb RMP1-14 (10 μg/ml;
Hölzel Diagnostika, Köln, Germany) or the respective rat IgG2a mAb 2A3 isotype control (10 μg/ml; Hölzel Diagnostika). Resulting SN was used in LL/2 luminescence assay. After 24h incubation, LNCM or LUCM was removed and LL/2 cells were treated with 15 μg/ml luciferin (Promega, Mannheim, Germany) to detect the luminescence intensity using the Centro XS³ LB 960 Microplate Luminometer (Berthold Technologies, Bad Widlbach, Germany). Respective cell numbers were calculated by using a standard curve.
Apoptosis analysis of LL/2-luc-M38 cell
For apoptosis analysis 7 x 10 3 LL/2-luc-M38 (LL/2) cells were seeded in 96 well plates in DMEM medium supplemented with 10% FCS, 1% Pen/Strep and 1% L-Glu. IncuCyte™ Caspase-3/7
Reagent (Essen BioScience, Ann Arbor, Michigan, US) was used at a final concentration of 1 μM [30] and in vitro re-challenged with αPD-1 mAb RMP1-14 (10 µg/ml; Hölzel Diagnostika) or the respective rat IgG2a mAb 2A3 isotype control (10 µg/ml; Hölzel Diagnostika) for 24h followed by flow cytometry analyses.
Hematoxylin and Eosin (H&E) staining on murine paraffin embedded lung sections
Lungs were removed, fixed in 10% formalin-PBS solution, dehydrated, and embedded in paraffin.
Five-micrometer-thick lung sections from paraffin blocks were stained with hematoxylin and eosin for visualization of lung tumours.
Flow cytometry analyzes of murine cells
Single cell suspensions from murine lungs were prepared as previously described [30] . 
In vitro analysis of lung CD8 + T-cells
Single cell suspensions from murine lungs were prepared as previously described [30] .
CD8
+ T-cells were isolated from the lungs of naïve and tumour-bearing mice by magnetic cell separation using the CD8a (Ly-2) MicroBeads, mouse kit (Miltenyi Biotec) in accordance to the manufacturer's instructions. The purity of the isolated CD8 + T-cells was confirmed by FACS analysis. CD8 + T-cells were then cultured in RPMI-1640 medium (Gibco) containing 10% FCS, 1% Pen/Strep and 1% L-Glu and stimulated with αCD3 (10 μg/ml; BD Bioscience) and αCD28
(1 μg/ml; BioLegend) antibodies. After 48h, CD8 + T-cells were harvested and resuspended in 500 µl 75% cold EtOH added dropwise. Cells were incubated for 24h at -20°C. Fixed cells were then washed twice with 1 ml wash buffer (PBS with 1% FCS, 0.09% NaN 3 pH 7.2) and stained with PI (BD Bioscience) staining solution (1:85 in wash buffer), followed by flow cytometric analyses by using FACS Canto II (BD BioScience).
Statistical analysis
Statistics were computed with Graph-Pad Prism7. The unpaired t-test was performed for parametric data containing no more than two groups. Data are presented as mean ± SEM and significance levels indicated as follows: * p<0.05, ** p<0.01, ***p<0.001.
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Results
Loss of NFATC1 in the tumoural region correlates with poor prognosis in NSCLC patients
In this study we started to investigate the role of NFATc1 in NSCLC by analyzing its mRNA expression in the tumoural (TU, solid tumour), peri-tumoural (PT, 2 cm around the solid tumour) and control lung region (CTR, tumour-free control area) of our cohort of patients with lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SCC), collectively grouped as NSCLC (Table 1) . Here we found a significantly decreased expression of NFATC1 mRNA in the TU region of patients with both ADC and SCC as compared to the respective PT and CTR region (Fig. 1a) . Accordingly, higher amounts of total NFATc1/β-Actin protein levels were found in the CTR and PT region of ADC patients whereas in the TU region total NFATc1/β-Actin protein levels decreased (Fig. 1b, Suppl. 1a) . In addition, we analyzed the phosphorylation status of NFATc1 (pNFATc1) as dephosphorylation of NFAT proteins leads to their activation in terms of nuclear translocation [3] . As a result, we found no differences in pNFATc1/β-Actin and pNFATc1/NFATc1 protein levels in the CTR, PT and TU regions ( Fig. 1b; Suppl. 1a) . We next analyzed the NFATC1 mRNA expression in different disease stages according to the TNM classification describing the size of the primary tumour, the degree of spread to regional lymph nodes and the presence of distant metastasis. We found that, in the tumoural area, NFATC1 mRNA expression decreased as the tumour stadium progressed (Fig. 1c) . Moreover, using immunohistochemical double staining for NFATc1 and CD3 on lung tissue arrays obtained from our cohort of patients, we demonstrated a downregulation of NFATc1 in CD3 + T-cells in the tumoural region of advanced NSCLC stages (Fig. 1d, Suppl. 1b) . Furthermore, flow cytometry revealed an increase of NFATc1 in CD8 + T-cells in the PT region as compared to the respective TU region of ADC patients (Fig. e) , whereas in CD4 + T-cells no differences of NFATc1 could be observed (Suppl. 1c). In addition, NFATc1 was found to be tendentially increased in (Fig. 1f) in the CTR and PT region as compared to the respective TU region.
No regional regulation was observed in the distribution of NFATc1 in CD4 expression in the PT region (Fig. 1g) whereas no direct correlation was found in the CTR and TU region (Suppl. 1e). Moreover, NFATC1 directly correlates with TBX21 expression (Fig. 1h) , a gene that codes for Tbet (T-box transcription factor TBX21), the main transcription factor controlling IFNγ production in T-cells [31] . In general, these results indicate a downregulation of NFATc1 in T-cells in the presence of NSCLC and at the advanced disease stage. Furthermore,
+ T-cells were found induced in the CTR and PT region of the lung of ADC patients confirming recent findings that T-cells in these patients are exhausted [32] and thus, represent the target for the αPD1-tumour immunotherapy. Because NFATc1 controls the IL-2 promoter, we next correlated NFATC1 with IL2 and its receptor subunits IL-2Rα (CD25), IL-2Rβ
(CD122) and IL-2Rγ (common cytokine receptor γ, CD132) [33] . We found that in the TU region NFATC1 expression directly correlates with IL2 as well as CD122 and CD132 (Fig. 1i) but not with CD25 (Suppl. 1f). The IL-2Rα chain is present on T effector as well as T regulatory cells.
By contrast, the IL-2Rβ and IL-2Rγ chain are characteristic for memory T-cells [34, 35] , indicating a potential role of NFATc1 in T-cell memory expansion. In accordance to this, we found a direct correlation of NFATC1 with the T memory cell markers IL7 in the CTR region as well as CD127 (IL-7Rα) [36] in both the CTR as well as TU region of NSCLC patients (Fig. 1j) .
Influence of siRNA-mediated knockdown of NFATc1 in human lung tumour cells on the response to PD-L1 inhibitors
Likewise PD-1 (Programmed cell death protein-1) which is highly expressed on TILs in many cancer types, its ligand PD-L1 is commonly upregulated on the tumour cell surface of different human tumours including lung cancer [37, 38] . Based on this notion, we analyzed if there is a relation between NFATc1 and PDL-1 in NSCLC development. We found a direct correlation between NFATc1 and PD-L1 in the TU region of patients suffering from NSCLC (Fig. 2a) .
Furthermore, lung cancer is of epithelial cell origin and thus, we analyzed NFATc1 in epithelial cells of the lung of these patients by using an epithelial specific antibody (anti-EpCAM whereas in the CTR region, a modest proportion of EpCAM + cells expressing both NFATc1 and PD-L1 could be detected (Fig. 2b) . We next analyzed the influence of NFATc1 on the response to PD-L1 inhibitors in lung tumour cells. To this aim we knocked down the expression of NFATC1 in the human lung adenocarcinoma cell line A549 using NFATC1-directed siRNA (siNFATc1)
followed by treatment with an αPD-L1 antibody (αPD-L1) (Fig. 2c) . In this experimental setting,
we achieved a specific NFATC1-knock-down as compared to non-targeting siRNA (siNT) after both αPD-1 and IgG2b isotype control treatment (Fig. 2d) . we counted A549 cells and found that NFATC1 knock-down with or without αPD-L1 antibody treatment did not affect the overall numbers of living A549 (Fig. 2f) . Furthermore, analysis of apoptosis induction using Annexin (Ann)V/PI staining revealed a slight increase of AnnV + PI + late apoptotic A549 cells after siRNA-mediated NFATC1-knock-down in combination with PD-L1 blockade compared to A549 cells transfected with siNT and treated with IgG2b (Fig. 2g) . In addition, αPD-L1 antibody treatment of A549 cells in which NFATC1 was knocked-down induced a slight expansion of AnnV -PI + dead A549 cells as compared to the IgG2b treatment (Fig. 2g) . As we detected only a modest expression of PD-L1 by A549 cells (Fig. 2e) , we subsequently stimulated them with IFNγ followed by siRNA-mediated NFATC1-knock-down and αPD-1 antibody treatment (Fig. 2h) . IFNγ has been shown to induce PD-L1 in human airway epithelial cells [39] . Furthermore, stimulation of A549 cells with IFNγ mimics host immune responses as this cytokine is predominantly produced by T helper 1 (Th1) cells as well as cytotoxic CD8 + T-cells to mediate successfully anti-tumoural immune responses [40] . In this experimental setting, downregulation of NFATc1 mRNA was observed by siRNA-mediated NFATC1-knock-down and maintained after αPDL-1 antibody treatment (Fig.2i) .While stimulation of A549 cells with IFNγ induced a strong increase in PD-L1 + PD-1 -A549 cells (Fig. 2j) 
down did not influence the growth of A549 tumour cells neither in combination with αPD-L1 nor with IgG2b (Fig. 2k) . Regarding PD-1 expression, again we only detected a low proportion of
-A549 cells (Fig. 2j) . Altogether, NFATc1 expressed in tumour cells has no influence, neither on tumour cell growth nor on their response to αPD-L1 antibody treatment.
Targeted deletion of NFATc1 in T-cells causes severe lung tumour development
As we demonstrated that NFATc1 expression in tumour cells has no influence on the tumour cell growth and response to αPD-L1 antibody treatment (Fig. 2) , we started to investigate the role of NFATc1 in T-cells in a murine model of lung adenocarcinoma, a condition that closer resemble the human condition in NSCLC. Lung tumour development was induced by intravenous injection of LL/2-luc-M38 (LL/2) cells followed by the analysis of tumour growth via an in vivo bioluminescence based imaging system (Fig. 3a) . Here we observed a down-regulation of NFATc1α in CD4 + T-cells isolated from the lung of mice suffering from lung adenocarcinoma (LL/2) as compared to those isolated from naïve control mice (naïve) (Fig. 3b) , indicating that Here we found that, targeted deletion of NFATc1 in T-cells resulted in increased lung tumour growth as shown by bioluminescence in vivo imaging (Fig. 3c) and histological analysis indicating increased infiltration of tumour cells into the lung (Fig. 3d) . Furthermore, we could demonstrate that Nfatc1 was successfully deleted in T-cells of NFATc1 ΔCD4 mice as shown by decreased Nfatc1 mRNA expression in isolated lung CD8 + T-cells (Fig. 3e) and splenic CD4 + T-cells (Fig. 3f) .
NFATc1 influences tissue homeostasis and differentiation of memory CD8 + T-cells
NFATc1 is highly expressed in peripheral T-cells and important for their activation and cytotoxic function [5, 7] . Thus, we next analyzed if the increased tumour growth in NFATc1 ΔCD4 mice could (Fig. 4a) . In NFATc1 ΔCD4 mice bearing lung tumour, these CD8 + T-cells are characterized by a decreased expression of CD25 (IL-2R) (Fig. 4b) as well as by a diminished proliferative capacity indicated by a reduced proportion of CD8 + T-cells in the G2/M phase of the cell cycle (Fig. 4c) . Furthermore, while we found no differences in the IL-2 production by lung CD8 + T-cells, we could show a strong decrease in IL-2 produced by CD8 + T-cells in the spleen of NFATc1 ΔCD4 tumour-bearing mice (Fig. 4d) . A reduced production of IL-2 by CD8 + T-cells is a characteristic feature of T-cell exhaustion [41] . Moreover, CD8 + memory T-cells relay on autocrine IL-2 production which enables optimal secondary population expansion and promotes a robust response in advanced tumour-bearing states [13] .
Memory CD8 + T-cells are heterogeneous with respect to phenotypic markers, effector functions and tissue-homing capabilities and are classified into central memory T-cells (TCM), effector memory T-cells (TEM) and tissue-resident memory T-cells (TRM). TCM cells reside in
secondary lymphoid organs and provide protection from a systemic challenge while TEM cells are highly reactive for immediate protection and circulate between lymphoid organs and peripheral tissues or inflammatory sites [15] . In the spleen of tumour-bearing NFATc1 ΔCD4 mice we found an increase in TCM cell populations and a trend towards reduction of TEM cells (Fig.   4e) . Furthermore, in the tumour-bearing lung of NFATc1 ΔCD4 mice TEM cells were significantly decreased (Fig. 4f) underlining an impaired cytotoxic T-cell response in these mice. TRM cells occupy tissues and mucosal sites such as the lung and are characterized by the lack of recirculation via the bloodstream which is important for long-term regional immunity. The surface molecule integrin αE CD103 is linked to TRM cells and promotes their localization to epithelia [16] . Furthermore, NFATc1 has been shown to induce the expression of the Itgae gene encoding CD103 [9] . Consistently, we found a decreased proportion of CD103 + TRM cells in the lung of tumour-bearing NFATc1 ΔCD4 mice (Fig. 4g) 
Cytokines secreted from NFATc1 ΔCD4 dLNs support tumour cell growth
Since we found a decreased expression of NFATc1α in lung CD4 + T-cells of tumour-bearing wild-type mice (Fig. 3b) , we analyzed the influence of the conditional inactivation of NFATc1 in T-cells on CD4 + T-cell properties in NFATc1 ΔCD4 mice. While we could not detect a difference in the proportion of lung CD4 + T-cell populations neither in naïve nor in tumour-bearing NFATc1 ΔCD4 mice (Suppl. 2a), we found that in the absence of NFATc1, lung CD4 + T-cells express a lower amount of the activation marker CD25 (IL-2R) (Fig. 5a) . Furthermore, lung CD4 + T-cells of tumour-bearing NFATc1 ΔCD4 mice but not of naïve mice are characterized by a reduced production of IL-2 (Fig. 5b, Suppl. 2b) , important for T-cell proliferation, survival and activation [14] . The observed reduction of IL-2 production by lung CD4 + T-cells was even more dramatically reduced by CD4 + T-cells in the spleen of tumour-bearing NFATc1 ΔCD4 mice (Fig. 5b) . In addition, reduced CD4 + T-cell proportions in the spleen and the draining lymph nodes (dLN) of naïve and tumour-bearing NFATc1 ΔCD4 mice (Fig. 5c (Fig. 5e) . We could show that, LNCM of tumour-bearing NFATc1 ΔCD4 mice significantly increased LL/2 cell numbers as compared to LNCM of tumour-bearing NFATc1 fl/fl control littermates (Fig. 5f ). In addition, we analyzed the influence of supernatants of total lung cells (=lung-conditioned medium, LUCM) but could not observe any effect on LL/2 cell proliferation (Suppl. 2d, e). Thus, LNCM but not LUCM of NFATc1 ΔCD4 mice contain soluble factors that promote LL/2 lung tumour cell survival. To start to identify this factor, we analyzed the presence of different cytokines and growth factors. While VEGFA, IFNγ and IL-10 were not found to be differentially regulated (Suppl. 2f, g, h), we observed a decrease of TNFα, IL-2 and IL-7 in LNCM of NFATc1 ΔCD4 mice (Fig. 5g, h, i) . Moreover, we could show that TNFα, an antitumoural cytotoxic molecule, induces apoptosis in LL/2 cells (Fig. 5j) . In summary, during lung adenocarcinoma development, the loss of NFATc1 in CD4 + T-cells resulted in decreased CD4 + T-cell activation and IL-2 production in both the lung and secondary lymphoid organs.
Furthermore, we could show that NFATc1 up-regulates anti-tumour cytokines in the dLNs of tumour-bearing NFATc1 ΔCD4 mice.
αPD-1 antibody treatment induced NFATc1 in CD4 + and CD8 + T-cells
In our cohort of patients we observed an increase of NFATc1 in CD8 + PD-1 + T-cells in the CTR and PT region (Fig. 1f) confirming recent findings that T-cells in these patients are exhausted [32] probably because of chronic activation via the tumour antigen. (Fig. 6a) . In terms of survival (Fig. 6b) and weight change (Fig. 6c) 
21
18 p.i. (Fig. 6d) . As we could not observe a difference in lung cancer development after αPD-1 treatment we re-challenged total cells from the lungs of these mice with αPD-1 or IgG2a in vitro for 24h (Fig. 6a) . Re-challenging the lung cells in vitro with αPD-1 antibodies induced a strong increase of NFATc1 in both CD4 + and CD8 + T-cells from about 70% up to 90% (Fig. 6e, f,   Suppl. 3a, b) . Afterwards, we applied supernatants of the re-challenged total lung cells (LUCM)
in a cytotoxicity assay with LL/2 tumour cells used to induce lung tumour growth in mice (Fig. 6   g ). As a result we observed a reduction in LL/2 cell growth induced by LUCM of total lung cells obtained from mice bearing tumour and in vitro re-challenged with αPD-1 as compared to IgG2a (Fig. 6h) . Collectively these data demonstrate a strong induction of NFATc1 in T-cells by αPD-1 antibody treatment which seems to inhibit LL/2 lung tumour growth via a soluble released factor.
These are very supportive and challenging results in T-cells as a new therapeutic avenue for NSCLC.
Discussion
In our present study we demonstrated an important function of NFATc1 for successful T-cell mediated anti-tumoural immune responses in the setting of NSCLC. In our human patient cohort, we found a downregulation of NFATc1 in T-cells in the presence of NSCLC and at advanced disease stages indicating that a loss of NFATc1 in T-cells is associated with poor prognosis. Upon T-cell activation, NFATc1 regulates the expression of numerous genes controlling the activity and fate of T-cells. Among them IL-2, which has been shown to be important for T-cell activation, proliferation and survival as well as for CD8 + effector and memory T-cell generation [9, 14, 17] .
Accordingly, we found a direct correlation between NFATc1 and IL-2 as well as its receptor subunits CD122 and CD132 but not CD25. While immunosuppressive T regulatory cells are characterized by the expression of all three IL2-R subunits, CD122 and CD132 are characteristic for memory T-cells and NK cells [34, 35] . Among fate markers for memory T-cells, the IL7R genes are NFATc1 targets [9] . According to that, NFATc1 correlates with the IL7Rα chain as well as with IL-7 implicated in CD8 + memory T-cell differentiation and homeostasis [9, 36] . In addition, NFATc1 directly correlates with Tbet, the main transcription factor controlling IFNγ that is relevant for the cytotoxic anti-tumour activity of TIL [31] , which was found downregulated in the CD8 + T-cells isolated from the tumoural region of our cohort of patients with NSCLC [27] .
Thus, in the tumoural and control region of NSCLC patients, NFATc1 correlates with factors that are characteristic for cytotoxic and memory T-cell responses and seems to be important for antitumoural immunity.
In our murine model of lung adenocarcinoma we found a decreased expression of NFATc1α in lung CD4 + T-cells of tumour-bearing wild-type mice. Moreover, targeted deletion of NFATc1 in T-cells (NFATc1 ΔCD4 ) resulted in increased lung tumour growth which was associated with an impairment of CD4 + and CD8 + T-cells consistent with the importance of NFATc1 for T-cell activation and cytotoxic T-cell functions [5, 7] . We further detected reduced CD8 + T-cell proportions as well as decreased proliferation of CD8 + T-cells in the tumour-bearing lung of 
NFATc1
ΔCD4 mice. The production of IL-2 by lung CD8 + T-cells was not influenced while splenic CD8 + T-cells were characterized by a strongly decreased IL-2 secretion. IL-2 contributes to the primary as well as secondary expansion of CD8 + T-cells. Since the magnitude of T-cell expansion defines the number of memory CD8 + T-cells, IL-2 influences memory cell generation.
Furthermore, at the memory state, CD8 + T-cell frequencies can be strengthened by administration of IL-2 [13, 17] . Consistently, we found a reduction of TEM cell populations in the spleen and the lung of tumour-bearing NFATc1 ΔCD4 mice underlining an impaired cytotoxic T-cell response in these mice. Interestingly, splenic TCM cells of tumour-bearing NFATc1 ΔCD4 mice were significantly increased. The capacity to secrete IL-2 has been associated with TCM cells rather than TEM cells [15] . Thus, even though we detected an increased TCM cell population in the spleen of tumour-bearing NFATc1 ΔCD4 mice, we suggest that these cells are ineffective in secreting IL-2 as indicated by a reduced IL-2 production by splenic CD8 + T-cells. This reduced IL2 production could inhibit the development of splenic TEM cells as IL-2 signals are able to rescue CD8 + T-cells from cell death and provide an increase in CD8 + memory T-cell counts [17] .
Furthermore, as TEM cells circulate between lymphoid organs and peripheral tissue a decreased splenic TEM cell population is accompanied by a reduction in lung TEM cells in tumour-bearing NFATc1 ΔCD4 . A recent study described increased TCM and decreased TEM cell populations in the spleen of Listeria monocytogenes infected NFATc1 ΔCD4 [9] which is similar to the results we obtained in the murine lung adenocarcinoma model. Beside TEM and TCM cell populations we also analyzed the proportion of TRM cells, a unique tissue-resident memory T-cell subset important for enhanced regional immunity. TRM cells in various non-lymphoid tissues are characterized by the integrin αE CD103 which promotes the localization to epithelia [16] . In the tumour-bearing lung of NFATc1 ΔCD4 mice we found a strong decrease of CD103 + TRM cells consistent with the finding that NFATc1 has been shown to induce the expression of the Itgae gene encoding CD103 [9] . These results indicate that the tissue-homing capacity of lung TRM cells of tumour-bearing NFATc1 ΔCD4 mice is impaired. In addition, in a recent study a greater density of CD103 + TRM cells has been linked to an enhanced cytotoxicity of CD8 + T-cells and
was predictive for a better survival outcome of lung cancer patients [42] . Thus, a reduction in Immune checkpoint blockade with αPD-1 or αPD-L1 has proven to be a highly promising treatment of human cancers, including lung cancer [19, 22, 23] . As lung cancer is of epithelial cell origin and NFATc1 has been described to be expressed in mouse lung epithelial cells, [3, 25, 26] . Thus, the blockade of PD-1 restores TCR signaling, ensured the activation of Akt which inhibits GSK3 and promotes the activation of NFATc1 which induces T-cell activation and effector functions [7, 9, 25] .
Although preliminary, this is a very promising avenue: to challenge T-cells of patients with α-PD1
antibodies ex vivo to induce NFATc1 and promote T-cell activation followed by the transfer of these cells back into the patients to boost anti-tumoural T -cell responses. In fact, supernatants of lung cells re-challenged with α-PD1 antibodies inhibited LL/2 lung tumour cell growth supporting the importance of NFATc1 for T-cell mediated cytotoxic immune responses.
Research. T-primary tumour: 0: No evidence of primary tumour; 1a: Tumour 2 cm or less in greatest dimension; 1b: Tumour more than 2 cm but not more than 3 cm in greatest dimension; 2a:
Tumour more than 3 cm but not more than 5 cm in greatest dimension; 2b: Tumour more than 5 cm but not more than 7 cm in greatest dimension; 3: Tumour more than 7 cm; . N values are given per group. Data are shown as mean values ± s.e.m. using student´s twotailed t-test *P,0.05; **P,0.01, ***P,0.001.
